Mycophenolic Acid Articles

Access to many more medicines in Australia, as PBS list extended

28 October 2012

FDA Advisory Committee backs Bristol-Myers Squibb’s belatacept for prophylaxis of acute rejection in kidney transplant patients; firm names new CEO

3 March 2010

Study suggests TDM for at-risk CellCept patients

18 August 2008

FDA reissues warning on mycopheno drugs

26 May 2008

Stock Commentary - Europe - week to April 14, 2008

21 April 2008

FDA starts safety review of Roche's CellCept and Novartis' Myfortic after cases of PML

21 April 2008

Myfortic cuts GI effects in transplant recipients

14 January 2008

Israel's 2005 NHI drugs basket creates precedents for funding and registration

16 May 2005

Novartis' Myfortic launched in UK

20 September 2004

Stock Commentary - Europe

15 March 2004

Novartis' Myfortic cleared by FDA

8 March 2004

Novartis' Myfortic completes EU's MRP

16 February 2004

Novartis increases stake in Roche; 2003 results strengthen global position

2 February 2004

New Chemical Entities in 2003

19 January 2004

New data on Novartis transplant drugs

6 May 2002

Novartis' pipeline still a leader in pharma sector, despite recent setbacks

8 November 2001

Novartis files Myfortic in Europe

1 November 2001

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end